| Similar Articles |
|---|
 |
The Motley Fool
July 20, 2007
Brian Orelli |
Arena Keeps Burning the Cash The pipeline drugs being developed by Arena Pharmaceuticals hold promise, but it will be a while before, or if, the company shows a profit.   |
The Motley Fool
October 18, 2007
Billy Fisher |
Still Sleepless at Arena The drug company posts a wider third-quarter loss than a year ago. Investors, take note. |
The Motley Fool
September 26, 2007
Billy Fisher |
More Than 40 Winks From Arena The company announced positive preliminary results from its phase 2 clinical trial for APD125, which aims to treat people suffering from chronic insomnia. Investors, take note. |
The Motley Fool
May 27, 2011
Brian Orelli |
Don't Believe the Obesity Hype Meta-analysis data isn't going to help Arena Pharmaceuticals' obesity drug. |
The Motley Fool
March 30, 2009
Brian Orelli |
Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration. |
The Motley Fool
October 24, 2006
Brian Lawler |
Playing the AtheroGenics Waiting Game The results of phase 3 trials for the company's atherosclerosis drug will determine AtheroGenics' future. Investors, take note. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
September 27, 2006
Brian Lawler |
One Step Forward for InterMune The company's lead drug will enter phase 1 trials, bringing potential good fortune to investors. |
The Motley Fool
September 17, 2010
Brian Orelli |
Thanks for Nothing, Fen-Phen Arena gets knocked down despite a relatively clean side-effect profile. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
December 14, 2005
Stephen D. Simpson |
Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool
February 26, 2010
Brian Orelli |
A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
March 18, 2008
Brian Orelli |
Lack of Side Effects Doesn't Fatten Arena Good safety data on its obesity drug fails to plump up Arena's stock price. Investors, take note. |
The Motley Fool
March 21, 2007
Brian Lawler |
Acadia Ascending Shares of Acadia Pharmaceuticals soared by more than 100% following successful results from a phase 2 trial for schizophrenia drug candidate ACP-103. |
The Motley Fool
June 3, 2011
Brian Orelli |
FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully. |
The Motley Fool
March 14, 2008
Brian Orelli |
Weighing In on Obesity Drugs Could investing in drugmakers that produce weight-loss drugs help fatten your wallet? |
The Motley Fool
December 30, 2011
Brian Orelli |
Working Through the Obese To-Do List in 2011 Arena ends the year on an upswing. |
The Motley Fool
September 14, 2010
Brian Orelli |
42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
January 7, 2011
Brian Orelli |
A Biotech Roller Coaster Lexicon is back on the upswing. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
September 2, 2010
Brian Orelli |
Fatter Wallet. Up 22%. Still Risky. After VIVUS' Qnexa was shot down at its FDA advisory panel, it's clear that Arena and Orexigen have an uphill battle in front of them. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
The Motley Fool
December 22, 2010
Matt Koppenheffer |
Arena Pharmaceuticals Shares Plunged: What You Need to Know Shares of biopharma company Arena Pharmaceuticals dipped as much as 13% in intraday trading on massive volume. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
September 21, 2011
Brian Orelli |
Obesity-Drug Makers Stop Getting Bullied The drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval. |
The Motley Fool
February 1, 2011
Brian Orelli |
Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
November 20, 2006
Brian Lawler |
One-and-a-Half Setbacks for Exelixis Drug development is a long process usually involving many setbacks and failures, even for the most successful drug makers. Investors in this biotech shouldn't worry too much about this one. |
The Motley Fool
January 28, 2011
Brian Orelli |
Arena's Obese To-Do List The Food and Drug Administration's laundry list for Arena Pharmaceuticals seems to be getting longer. |
The Motley Fool
September 20, 2010
Brian Orelli |
Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time. |
The Motley Fool
September 18, 2009
Brian Orelli |
Up, Down, Up. Is This Stock a Home Run or Not? Shares of Arena Pharmaceuticals have been on a roller coaster after word that the company would release data for its obesity drug. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool
June 5, 2009
Brian Orelli |
Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
The Motley Fool
December 29, 2006
Brian Lawler |
Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide. |
The Motley Fool
January 10, 2007
Brian Lawler |
Seattle Genetics' Big Deal The small biopharmaceutical firm signed a lucrative collaboration deal with biopharma powerhouse Genentech and shares were up 24% as a result. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
July 2, 2010
Brian Orelli |
Arena Got Taken A billion-dollar market and that's all the pharmaceuticals company could get? |
